Shares of Agilent Technologies, Inc. (NYSE:A – Get Free Report) have received an average recommendation of “Moderate Buy” from the fourteen brokerages that are covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $146.15.
A number of brokerages have recently weighed in on A. Citigroup raised their price objective on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. Robert W. Baird cut their price target on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. Sanford C. Bernstein reduced their price objective on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 26th. Bank of America dropped their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th.
View Our Latest Stock Report on Agilent Technologies
Insider Activity
Institutional Trading of Agilent Technologies
Several large investors have recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of Agilent Technologies during the fourth quarter valued at approximately $456,963,000. Madison Investment Advisors LLC purchased a new stake in Agilent Technologies during the 4th quarter worth $94,051,000. Two Sigma Investments LP lifted its holdings in Agilent Technologies by 345.9% in the 4th quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company’s stock worth $103,428,000 after buying an additional 597,249 shares in the last quarter. Iron Triangle Partners LP purchased a new position in Agilent Technologies in the 4th quarter valued at about $80,110,000. Finally, Marshall Wace LLP grew its stake in shares of Agilent Technologies by 280.3% during the fourth quarter. Marshall Wace LLP now owns 806,895 shares of the medical research company’s stock valued at $108,398,000 after acquiring an additional 594,744 shares in the last quarter.
Agilent Technologies Stock Down 2.5 %
Agilent Technologies stock opened at $123.12 on Friday. Agilent Technologies has a fifty-two week low of $121.45 and a fifty-two week high of $155.35. The firm has a market capitalization of $35.12 billion, a price-to-earnings ratio of 28.30, a price-to-earnings-growth ratio of 3.59 and a beta of 1.11. The stock’s fifty day moving average is $140.22 and its two-hundred day moving average is $138.96. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20.
Agilent Technologies (NYSE:A – Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. The firm had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Analysts predict that Agilent Technologies will post 5.57 EPS for the current fiscal year.
Agilent Technologies Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be issued a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.81%. Agilent Technologies’s dividend payout ratio (DPR) is 22.76%.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
Further Reading
- Five stocks we like better than Agilent Technologies
- What is the Hang Seng index?
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Should You Invest in Penny Stocks?
- Tesla Stock: Finding a Bottom May Take Time
- Following Congress Stock Trades
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.